메뉴 건너뛰기




Volumn 364, Issue 25, 2011, Pages 2381-2391

Exemestane for breast-cancer prevention in postmenopausal women

(20)  Goss, Paul E a   Ingle, James N c   Alés Martínez, José E d   Cheung, Angela M n   Chlebowski, Rowan T e   Wactawski Wende, Jean f   McTiernan, Anne g   Robbins, John h   Johnson, Karen C i   Martin, Lisa W j   Winquist, Eric o   Sarto, Gloria E k   Garber, Judy E b   Fabian, Carol J l   Pujol, Pascal m   Maunsell, Elizabeth p   Farmer, Patricia q   Gelmon, Karen A r   Tu, Dongsheng s   Richardson, Harriet s  


Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARDIOVASCULAR AGENT; CELECOXIB; EXEMESTANE; PLACEBO;

EID: 79959403574     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1103507     Document Type: Article
Times cited : (858)

References (48)
  • 1
    • 0035945656 scopus 로고    scopus 로고
    • Estrogen and the risk of breast cancer
    • Erratum, N Engl J Med 2001;344:1804
    • Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85. [Erratum, N Engl J Med 2001;344:1804.]
    • (2001) N Engl J Med , vol.344 , pp. 276-285
    • Clemons, M.1    Goss, P.2
  • 2
    • 54049117698 scopus 로고    scopus 로고
    • Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women
    • Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:2029-35.
    • (2008) Cancer Epidemiol Biomarkers Prev , vol.17 , pp. 2029-2035
    • Eliassen, A.H.1    Missmer, S.A.2    Tworoger, S.S.3    Hankinson, S.E.4
  • 4
    • 0037123341 scopus 로고    scopus 로고
    • Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies
    • The Endogenous Hormones and Breast Cancer Collaborative Group
    • The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 606-616
  • 6
    • 0037464769 scopus 로고    scopus 로고
    • Overview of the main outcomes in breast-cancer prevention trials
    • DOI 10.1016/S0140-6736(03)12342-2
    • Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300. (Pubitemid 36126189)
    • (2003) Lancet , vol.361 , Issue.9354 , pp. 296-300
    • Cuzick, J.1    Powles, T.2    Veronesi, U.3    Forbes, J.4    Edwards, R.5    Ashley, S.6    Boyle, P.7
  • 7
    • 77953517123 scopus 로고    scopus 로고
    • Long-term follow-up in cancer prevention trials (It ain't over till it's over)
    • Phila
    • Cuzick J. Long-term follow-up in cancer prevention trials (It ain't over till it's over). Cancer Prev Res (Phila) 2010;3:689-91.
    • (2010) Cancer Prev Res , vol.3 , pp. 689-691
    • Cuzick, J.1
  • 10
    • 33745249570 scopus 로고    scopus 로고
    • Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    • Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
    • (2006) JAMA , vol.295 , pp. 2727-2741
    • Vogel, V.G.1    Costantino, J.P.2    Wickerham, D.L.3
  • 11
    • 33750985352 scopus 로고    scopus 로고
    • Prescription of tamoxifen for breast cancer prevention by primary care physicians
    • DOI 10.1001/archinte.166.20.2260
    • Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166:2260-5. (Pubitemid 44748773)
    • (2006) Archives of Internal Medicine , vol.166 , Issue.20 , pp. 2260-2265
    • Armstrong, K.1    Quistberg, D.A.2    Micco, E.3    Domchek, S.4    Guerra, C.5
  • 12
    • 33750575970 scopus 로고    scopus 로고
    • The dilemma and promise of cancer chemoprevention
    • DOI 10.1038/ncponc0609, PII NCPONC0609
    • Lippman SM. The dilemma and promise of cancer chemoprevention. Nat Clin Pract Oncol 2006;3:523. (Pubitemid 44781718)
    • (2006) Nature Clinical Practice Oncology , vol.3 , Issue.10 , pp. 523
    • Lippman, S.M.1
  • 13
    • 77954573787 scopus 로고    scopus 로고
    • Patient decisions about breast cancer chemoprevention: A systematic review and meta-analysis
    • Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 2010;28:3090-5.
    • (2010) J Clin Oncol , vol.28 , pp. 3090-3095
    • Ropka, M.E.1    Keim, J.2    Philbrick, J.T.3
  • 14
    • 67650333853 scopus 로고    scopus 로고
    • American Society of Clinical Oncology 2008 clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
    • Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology 2008 clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-58.
    • (2009) J Clin Oncol , vol.27 , pp. 3235-3258
    • Visvanathan, K.1    Chlebowski, R.T.2    Hurley, P.3
  • 17
    • 79954594388 scopus 로고    scopus 로고
    • Personalized estimates of breast cancer risk in clinical practice and public health
    • Gail MH. Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med 2011;30:1090-104.
    • (2011) Stat Med , vol.30 , pp. 1090-1104
    • Gail, M.H.1
  • 18
    • 0242541260 scopus 로고    scopus 로고
    • Breast cancer prevention - Clinical trials strategies involving aromatase inhibitors
    • DOI 10.1016/S0960-0760(03)00378-9
    • Goss PE. Breast cancer prevention - clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 2003;86:487-93. (Pubitemid 37412588)
    • (2003) Journal of Steroid Biochemistry and Molecular Biology , vol.86 , Issue.3-5 , pp. 487-493
    • Goss, P.E.1
  • 19
    • 0028594068 scopus 로고
    • Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats
    • Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994;15:2775-80.
    • (1994) Carcinogenesis , vol.15 , pp. 2775-2780
    • Lubet, R.A.1    Steele, V.E.2    Casebolt, T.L.3    Eto, I.4    Kelloff, G.J.5    Grubbs, C.J.6
  • 20
    • 0026518230 scopus 로고
    • Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors
    • De Coster R, Van Ginckel RF, Callens MJ, Goeminne NK, Janssens BL. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res 1992;52:1240-4.
    • (1992) Cancer Res , vol.52 , pp. 1240-1244
    • De Coster, R.1    Van Ginckel, R.F.2    Callens, M.J.3    Goeminne, N.K.4    Janssens, B.L.5
  • 22
    • 0142181118 scopus 로고    scopus 로고
    • Anastrozole Alone or in Combination with Tamoxifen versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early-Stage Breast Cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial Efficacy and Safety Update Analyses
    • DOI 10.1002/cncr.11745
    • Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10. (Pubitemid 37310221)
    • (2003) Cancer , vol.98 , Issue.9 , pp. 1802-1810
    • Baum, M.1    Buzdar, A.2    Cuzick, J.3    Forbes, J.4    Houghton, J.5    Howell, A.6    Sahmoud, T.7
  • 23
    • 29544433211 scopus 로고    scopus 로고
    • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    • The Breast International Group (BIG) 1-98 Collaborative Group. [Erratum, N Engl J Med 2006;354:2200.]
    • The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57. [Erratum, N Engl J Med 2006;354:2200.]
    • (2005) N Engl J Med , vol.353 , pp. 2747-2757
  • 24
    • 10744223655 scopus 로고    scopus 로고
    • A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    • Errata, 2004;351:2461, 2006;355:1746
    • Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. [Errata, 2004;351:2461, 2006;355:1746.]
    • (2004) N Engl J Med , vol.350 , pp. 1081-1092
    • Coombes, R.C.1    Hall, E.2    Gibson, L.J.3
  • 25
    • 78751647876 scopus 로고    scopus 로고
    • Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomized phase 3 trial
    • van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial. Lancet 2011;377:321-31.
    • (2011) Lancet , vol.377 , pp. 321-331
    • Van De Velde, C.J.1    Rea, D.2    Seynaeve, C.3
  • 27
    • 75749092296 scopus 로고    scopus 로고
    • Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
    • Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-18.
    • (2010) J Clin Oncol , vol.28 , pp. 509-518
    • Dowsett, M.1    Cuzick, J.2    Ingle, J.3
  • 28
    • 1542346356 scopus 로고    scopus 로고
    • The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats
    • DOI 10.1016/j.bone.2003.11.006, PII S8756328203004162
    • Goss PE, Qi S, Josse RG, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004;34:384-92. (Pubitemid 38314903)
    • (2004) Bone , vol.34 , Issue.3 , pp. 384-392
    • Goss, P.E.1    Qi, S.2    Josse, R.G.3    Pritzker, K.P.H.4    Mendes, M.5    Hu, H.6    Waldman, S.D.7    Grynpas, M.D.8
  • 30
    • 36549088561 scopus 로고    scopus 로고
    • Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
    • Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007;9:R52.
    • (2007) Breast Cancer Res , vol.9
    • Goss, P.E.1    Hadji, P.2    Subar, M.3    Abreu, P.4    Thomsen, T.5    Banke-Bochita, J.6
  • 31
    • 79959428142 scopus 로고    scopus 로고
    • Minimization Procedure
    • Chow SC, ed. 3rd ed. New York: Marcel Dekker
    • Tu D. Minimization Procedure. In: Chow SC, ed. Encyclopedia of biopharmaceutical statistics. 3rd ed. New York: Marcel Dekker, 2010:795-8.
    • (2010) Encyclopedia of Biopharmaceutical Statistics , pp. 795-798
    • Tu, D.1
  • 34
    • 0034671279 scopus 로고    scopus 로고
    • SF-36 health survey update
    • Phila Pa 1976
    • Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976) 2000;25:3130-9.
    • (2000) Spine , vol.25 , pp. 3130-3139
    • Ware Jr., J.E.1
  • 35
    • 0030199690 scopus 로고    scopus 로고
    • A menopause-specific quality of life questionnaire: Development and psychometric properties
    • Erratum, Maturitas 1996;25:231
    • Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-75. [Erratum, Maturitas 1996;25:231.]
    • (1996) Maturitas , vol.24 , pp. 161-175
    • Hilditch, J.R.1    Lewis, J.2    Peter, A.3
  • 37
    • 12344312699 scopus 로고    scopus 로고
    • version 3.0. March 31
    • Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. March 31, 2003. (http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.)
    • (2003) Common Terminology Criteria for Adverse Events
  • 38
    • 0037980149 scopus 로고    scopus 로고
    • Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation
    • Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92.
    • (2003) Med Care , vol.41 , pp. 582-592
    • Norman, G.R.1    Sloan, J.A.2    Wyrwich, K.W.3
  • 39
    • 0037357355 scopus 로고    scopus 로고
    • Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: An expert consensus panel report
    • DOI 10.1046/j.1525-1497.2003.20203.x
    • Wyrwich KW, Fihn SD, Tierney WM, Kroenke K, Babu AN, Wolinsky FD. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med 2003;18:196-202. (Pubitemid 36399456)
    • (2003) Journal of General Internal Medicine , vol.18 , Issue.3 , pp. 196-202
    • Wyrwich, K.W.1    Fihn, S.D.2    Tierney, W.M.3    Kroenke, K.4    Babu, A.N.5    Wolinsky, F.D.6
  • 40
    • 27244436756 scopus 로고    scopus 로고
    • Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women
    • Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931-40.
    • (2005) J Clin Oncol , vol.23 , pp. 6931-6940
    • Whelan, T.J.1    Goss, P.E.2    Ingle, J.N.3
  • 42
    • 41949094767 scopus 로고    scopus 로고
    • Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
    • Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051-7.
    • (2008) J Clin Oncol , vol.26 , pp. 1051-1057
    • Eastell, R.1    Adams, J.E.2    Coleman, R.E.3
  • 43
    • 77957708501 scopus 로고    scopus 로고
    • Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study
    • Coleman RE, Banks LM, Girgis SI, et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 2010;124:153-61.
    • (2010) Breast Cancer Res Treat , vol.124 , pp. 153-161
    • Coleman, R.E.1    Banks, L.M.2    Girgis, S.I.3
  • 45
    • 79953320008 scopus 로고    scopus 로고
    • Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial
    • Eastell R, Adams J, Clack G, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 2011;22:857-62.
    • (2011) Ann Oncol , vol.22 , pp. 857-862
    • Eastell, R.1    Adams, J.2    Clack, G.3
  • 46
    • 78649603622 scopus 로고    scopus 로고
    • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-Year analysis of the ATAC trial
    • Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-41.
    • (2010) Lancet Oncol , vol.11 , pp. 1135-1141
    • Cuzick, J.1    Sestak, I.2    Baum, M.3
  • 47
    • 37649008623 scopus 로고    scopus 로고
    • Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial
    • Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007;25:5715-22.
    • (2007) J Clin Oncol , vol.25 , pp. 5715-5722
    • Mouridsen, H.1    Keshaviah, A.2    Coates, A.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.